Tag - CYTK

Developments

Cytokinetics reports positive interim results from Phase 2 hypertrophic cardiomyopathy trial

Cytokinetics (NASDAQ:CYTK) reported positive interim results from the first cohort of its Phase 2 REDWOOD-HCM clinical trial evaluating CK-274 for the treatment of hypertrophic cardiomyopathy. In the first cohort, 21...

December 9, 2020

Developments

Cytokinetics reports mixed results from Phase 3 heart failure trial

Cytokinetics (NASDAQ:CYTK) reported primary results from its Phase 3 GALACTIC-HF trial evaluating omecamtiv mecarbil for the treatment of heart failure. Omecamtiv mecarbil is a novel selective cardiac myosin activator...

November 13, 2020

Developments

Cytokinetics gets FDA fast track designation for chronic heart failure drug candidate

Cytokinetics (NASDAQ:CYTK) omecamtiv mecarbil received FDA fast track designation for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). Omecamtiv mecarbil is a novel selective cardiac myosin...

May 8, 2020

Tag - CYTK

Cytokinetics reports positive interim results from Phase 2 hypertrophic cardiomyopathy trial

Cytokinetics reports mixed results from Phase 3 heart failure trial

Cytokinetics gets FDA fast track designation for chronic heart failure drug candidate

General

More